Patents Examined by Gregory S. Emch
-
Patent number: 11965024Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.Type: GrantFiled: September 10, 2021Date of Patent: April 23, 2024Assignee: Janssen Biotech, Inc.Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh, Michael Riis Hansen
-
Patent number: 11919945Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.Type: GrantFiled: November 4, 2021Date of Patent: March 5, 2024Assignee: The Rockefeller UniversityInventor: Michel Nussenzweig
-
Patent number: 11919953Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.Type: GrantFiled: July 14, 2021Date of Patent: March 5, 2024Assignee: AMGEN INC.Inventors: Sue J. Sohn, Marissa Mock, Ian Nevin Foltz, Agnieszka Kielczewska, Kathy Manchulenko, Yannick Bulliard, Xiaoshan Min
-
Patent number: 11883464Abstract: The present disclosure relates to the field of biopharmaceuticals and provides a nerve growth factor (NGF) fusion protein and a preparation method and use thereof. The fusion protein has a general formula represented by A-B or A-L-B, wherein A is a nerve growth factor, L is a linker peptide, and B is an Fc moiety of IgG, or an analogue of the Fc moiety of IgG, or a fragment of the Fc moiety of IgG. The fusion protein of the present disclosure has the following advantages over a wild-type NGF: higher biological activity, a half-life extended more than 17 times, greatly reduced administration frequency, and significantly increased efficacy.Type: GrantFiled: March 17, 2017Date of Patent: January 30, 2024Assignee: Staidson (Beijing) Biopharmaceuticals Co., Ltd.Inventors: Qingshuang Zhang, Lei Ma, Ming Liu
-
Patent number: 11760974Abstract: Human pluripotent stem cells are differentiated in vitro into oligodendro-spheroids comprising oligodendrocytes for use in analysis, screening programs, and the like.Type: GrantFiled: April 13, 2018Date of Patent: September 19, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Rebecca Marton, Sergiu P. Pasca
-
Patent number: 11733238Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.Type: GrantFiled: June 26, 2020Date of Patent: August 22, 2023Assignee: Prognosys Biosciences, Inc.Inventor: Mark S. Chee
-
Patent number: 11723951Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.Type: GrantFiled: June 18, 2020Date of Patent: August 15, 2023Assignee: Amyl Therapeutics SRLInventors: Rajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher, Francis J. Carr, Robert G. E. Holgate, Timothy D. Jones
-
Patent number: 11718666Abstract: Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.Type: GrantFiled: July 29, 2021Date of Patent: August 8, 2023Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventor: Rifaat Safadi
-
Patent number: 11661585Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.Type: GrantFiled: April 6, 2020Date of Patent: May 30, 2023Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
-
Patent number: 11643446Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.Type: GrantFiled: March 17, 2022Date of Patent: May 9, 2023Assignee: Denali Therapeutics Inc.Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
-
Patent number: 11643448Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).Type: GrantFiled: June 26, 2018Date of Patent: May 9, 2023Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Daisuke Sasaki
-
Patent number: 11613737Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.Type: GrantFiled: April 6, 2020Date of Patent: March 28, 2023Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
-
Patent number: 11598774Abstract: Provided are methods of mitigating, reversing or eliminating in a subject one or more symptoms associated with cognitive impairment associated with amyloid deposits in the brain (e.g., olfactory dysfunction as a risk factor of dementia, mild cognitive impairment, Alzheimer's Disease) by detecting and targeting gram negative bacteria in the brain.Type: GrantFiled: April 23, 2019Date of Patent: March 7, 2023Assignee: The Regents of the University of CaliforniaInventors: Xinhua Zhan, Boryana S. Stamova-Kiossepacheva, Frank R. Sharp
-
Patent number: 11591379Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.Type: GrantFiled: March 16, 2020Date of Patent: February 28, 2023Assignee: Janssen Pharmaceutica NVInventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
-
Patent number: 11571485Abstract: The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described here are unique in the field and can be expected to advance understanding on early neurodegenerative changes associated with AD and improve the therapeutic outcomes by early detection and intervention in AD. Further, the invention provides antibodies that can be used to treat AD.Type: GrantFiled: November 16, 2017Date of Patent: February 7, 2023Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
-
Patent number: 11573229Abstract: The present invention relates to automated methods for isolating fetal cells from a sample, such as a blood sample, derived from a pregnant woman. The isolated fetal cells can be used for identifying genetic abnormalities in the fetal DNA.Type: GrantFiled: February 23, 2021Date of Patent: February 7, 2023Assignee: Arcedi Biotech ApSInventors: Bolette Hestbek Nicolaisen, David Mathias Martin Leiding Kolvraa, Inga Baasch Christensen, Katarina Ravn, Line Dahl Jeppesen, Lotte Hatt, Palle Scheide Jensen, Ripudaman Singh
-
Patent number: 11542316Abstract: The present invention relates to a composition which comprises peptides derived from S-Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, which is useful in the treatment and/or prevention of uveitis.Type: GrantFiled: January 4, 2018Date of Patent: January 3, 2023Assignee: Worg Pharmaceuticals (Zhejiang) Co., Ltd.Inventors: David Wraith, Evelien Schurgers, Keith Martin, Liselotte Jansson
-
Patent number: 11542322Abstract: Provided are aggregate alpha-synuclein specific antibodies as well as fragments, derivatives, and variants thereof as well as method related thereto for the early diagnostic and treatment of Parkinson's Disease and other Lewy body- and Lewy neurite-based diseases. Assays, kits, systems, and nanoparticle encapsulated compositions related to the antibodies or fragments, derivatives, and variants thereof are also disclosed.Type: GrantFiled: February 13, 2020Date of Patent: January 3, 2023Assignee: Iowa State University Research Foundation, Inc.Inventors: Balaji Narasimhan, Surya Mallapragada, Anumantha G. Kanthasamy, Manohar John, Vellareddy Anantharam
-
Patent number: 11536731Abstract: Methods and systems directed to monitoring for the presence or progression of amyloid diseases via detection of amyloid fibrils in a sample from an individual are disclosed. An individual, or sample from an individual, is treated with a reagent including a fluorescent protein. The fluorescent protein in the reagent binds to amyloid fibrils present in the sample. Detecting a signal from fluorescent protein bound to the treated sample indicates the presence of amyloid fibrils in the sample and possible diagnosis of an amyloid disease. The presence and progression of an amyloid disease is monitored by quantifying signal intensity from samples taken over time. Treatment with a reagent including a fluorescent protein inhibits amyloid fibril formation by providing the reagent to an environment including amyloid monomers. The fluorescent protein binds to amyloid oligomers during the lag phase and/or elongation phase of amyloid fibril formation, preventing formation of mature amyloid fibrils.Type: GrantFiled: January 23, 2018Date of Patent: December 27, 2022Assignee: Rensselaer Polytechnic InstituteInventors: George I. Makhatadze, Changmingzi Xu-Fuery, Josephine Grace LoRicco, Nathan James, Anthony Charles Bishop
-
Patent number: 11535661Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.Type: GrantFiled: September 17, 2021Date of Patent: December 27, 2022Assignee: BIOAGE LABS, INC.Inventors: Robert Hughes, William Strohl